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Introduction Proton pump inhibitors (PPIs) are one of the commonest drug prescribed, 
however it is not without risk of adverse effects especially if the usage is 
inappropriate. We aimed to evaluate the frequency, indications and 
appropriateness of PPIs prescription among the medical inpatients, Serdang 
Hospital, which is a tertiary hospital in Malaysia. 
Methods This is a cross sectional study consisting of 1184 patients admitted to medical 
ward and received PPI from 1st July 2016 to 31st March 2017, and their 
database were further analysed by SPSS Statistics 17.0. Unpaired t-test was 
performed to analyze the data collected. P < 0.05 (two-tailed) is considered 
significant. Their indications were cross-referenced against the indications 
adapted from the United States Food and Drug Administration (FDA). 
Results About 23.9% (1184/4953) of inpatients were using PPIs, and 63.0% 
(746/1184) of them recently started on PPI in the ward, with mean age of 59.7 
years. More male patients were commenced on PPIs during hospitalization (P 
value < 0.05). Based on the FDA guideline, only 21.8% patients were 
indicated, 32.2% were borderline indicated, and 46.0% patients were not 
indicated in prescribing PPIs. Stress ulcer prophylaxis was the commonest 
indication, while anaemia with no evidence of gastrointestinal bleed was the 
main non-indication in starting PPIs. Only 11% of patients had performed the 
oesophago-gastro-duodenoscopy (OGDS) during the hospital stay. 
Conclusions 46.0% of inpatients were inappropriately prescribed PPIs according to FDA 
guideline. More efforts should be initiated to improve the current situation of 
PPIs overutilization in Malaysia. 
Keywords Proton pump inhibitor - Overutilization - Appropriateness. 
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INTRODUCTION 
Proton pump inhibitors (PPIs) are currently the most 
effective agents for acid-related disorders. PPIs have 
been used for treatment of Helicobacter Pylori 
infection, Gastro – Esophageal Reflux Disease 
(GERD), peptic ulcer disease and pathological 
hypersecretory conditions such as Zollinger–Ellison 
syndrome. For most indications, the patients should 
only take PPI for four to twelve weeks. However, the 
use of PPIs has significantly increased since the first 
PPI, omeprazole first came to market in 1980s. In a 
US study estimating the prevalence of visits in 
which patients used PPIs by SR Rotman et al., it was 
found that PPIs were prescribed in 4.0% of visits in 
2002 and increased to 9.2% of visits in 2009 (p < 
0.001), and more surprisingly that 62.9% of them 
were prescribed without clear indication.1 The 
dramatic increase in PPIs prescription may be 
inappropriate and do not conform to evidence-based 
indications or even according to United States Food 
and Drug Administration (FDA) guideline on PPIs 
usage. Ample epidemiology studies over the past 
decade have reported the inappropriate PPIs 
prescription either inpatient or outpatient. And this 
even can lead to additional wastage of medical 
healthcare.2,3 A questionnaire-based study which 
was done in an Irish regional hospital showed 45.0% 
of patients were on PPIs with no valid indication, 
and 31.0% of them were taking PPI for at least two 
years.4 Additionally, a Peru study showed a 54.6% 
of PPIs overuse in two academic hospitals which 
was not based on Clinical Practice Guideline (CPG). 
5 While in Asia, Christopher Chia TW et al.6 had 
published a study which involved 477 inpatients in 
a Singapore Hospital that less than 50.0% of their 
patients were prescribed PPIs according to FDA 
guideline. 
There are also growing concerns about the 
possible side effects of PPIs which are increasing 
with longer and wider use of PPIs. The long-term 
safety of these medications, as well as potentially 
important drug interactions has become the subject 
of debate. Omeprazole is ranked on the top four 
among the highest expenditure of the most 
prescribed medicines in Malaysia.7 Few recent 
studies had demonstrated inappropriate PPI 
prescription in Malaysian hospitals.8-9 Therefore, we 
aimed to run this study to identify the prevalence, 
indications and appropriateness of PPIs prescription 
among the patients in general medical ward, 
Serdang Hospital, which is a tertiary hospital in 
Selangor, Malaysia.  
 
METHODS 
Our study is a cross sectional study design. All 
patients who were admitted to general medical ward 
from 1st July 2016 to 31st March 2017 (nine months 
period) and recently started on PPIs in the ward were 
recruited in our study, and their database 
(demography, presenting complains, working 
diagnosis, physical examinations, lab investigations 
and management plan) were further analysed by 
SPSS Statistics 17.0. Unpaired t-test was performed 
to analyze the data collected. χ2 or Fisher’s exact 
test, where appropriate, was used for analysis of 
categorical variables. P < 0.05 (two-tailed) is 
considered significant. Our hospital uses Electronic 
Medical Record (EMR) system in patient registry, 
and the patients’ data can be completely kept and 
accessed over time. Furthermore, EMR system had 
the advantage that the type of PPIs given and the 
indications of the PPI including those already on 
PPIs before hospitalization were able to be reviewed 
base on the documentation of symptoms, endoscopy 
findings and clinical circumstances. Currently, there 
is no national guideline of prescription of PPIs in 
Malaysia. The United States FDA guideline for 
usage of PPIs had been applied in this study, and the 
indications for the use of PPIs were shown in Table 
1. Those patients on PPIs were further categorised 
into three groups: (a) fulfilled the FDA indications; 
(b) no clear indications; and (c) borderline 
indications. This project was registered with the 
National Medical Research Register and approved 
by the Medical Research Ethics Committee, 
Malaysia prior to the commencement of the study. 
 
Table 1 Indications for the use of PPIs accepted by United States FDA10 
 
United States FDA accepted indications for the use of PPIs 
Peptic ulcer disease 
Erosive esophagitis 
Helicobacter pylori 
Gastro-esophageal reflux disease 
Pathological hypersecretory conditions 
Stress ulcer prophylaxis 
 
Other accepted or off labelled usage of PPIs as per United States FDA 
Risk reduction of NSAID-associated peptic ulcer disease in patients on NSAIDs 
with >2 of the following risk factors : 
- Age >65 years old 
- History of peptic ulcer disease or upper gastrointestinal tract bleeding 
- High dose NSAID therapy 
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- Concomitant NSAID use with an anticoagulant, antiplatelet or 
glucocorticoid 
Esophageal stricture ( peptic ) 
Barret’s esophagus 
To improve pancreatic enzyme absorbtion in cystic fibrosis 
Uninvestigated dyspepsia ( short term trial, investigation required, if persistent ) 
 
RESULTS 
A total of 4953 patients had been admitted to general 
medical ward from 1st July 2016 to 31st March 2017. 
Retrospectively, 23.9% (1184/4953) of them were 
using PPIs during their ward admission. Among 
1184 patients, 37.0% of them already used a PPI 
even before their hospitalization, which was 
assumed to be initiated by their primary care 
physicians or during their previous hospital 
visits. Therefore, only those who were recently 
started on PPIs in the ward (n=746) were recruited 
in the current study. The mean age of patients was 
59.7 years, with 45.6% (340/746) of the patients 
were of 60-79 year old age group, followed by 
40.8% (304/746) of 30-59 year old age group. 58.2% 
of them were male. In terms of ethnics, the 746 
patients comprised 371 Malays, 190 Chinese, 152 
Indians and 33 others. An overview of 
demographics of the patients regarding their gender, 
ethnicity, and age group were summarized in Table 
2.  
 
Table 2 Socio-dermographic of inpatients on PPIs 
 
    Variables                                   Frequency, n (percentage, %)    
Gender 
Male                                                        434 (58.2)                                     P value = 0.045 
Female                                                    312 (41.8) 
Ethnicity 
Malay                                                      371 (49.7)                                    P value = 0.093 
Chinese                                                   190 (25.5) 
Indian                                                      152 (20.4) 
Others                                                       33 (4.4) 
Age group 
younger than 30 years old                        44 (5.9)                                       P value = 0.979 
30-59                                                      304 (40.7) 
60-79                                                      340 (45.6) 
More than 80 years old                           58 (7.8) 
Total                                                      746 (100.0) 
 
Pantoprazole and omeprazole accounted 
for 81% of overall PPIs prescriptions, as shown in 
Table 3.  
 
Table 3 Types of PPIs prescription during ward admission 
 
   Type of PPIs                                      Frequency, n (percentage, %)    
Omeprazole                                                            289(38.8) 
Pantoprazole                                                           315(42.2) 
Esomeprazole                                                         136(18.2) 
Lansoprazole                                                              6(0.8) 
Total                                                                      746 (100.0) 
 
It was alarming that only 11% (82/746) of 
the patients had performed the oesophago-gastro-
duodenoscopy (OGDS) during the hospital stay for 
justification for being on PPIs. 
Based on the United States FDA guideline 
for usage of PPIs, 21.8% (163/746) patients were 
indicated, 32.2% (240/746) were borderline 
indicated and 46.0% (343/746) patients were not 
indicated in prescribing PPIs (see Figure 1).  
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Figure 1 Proportion of patients started on PPIs during ward admission according to the United States FDA 
guideline 
 
As illustrated in Figure 2, among the 163 
patients who were indicated for PPIs, stress ulcer 
prophylaxis (64.4%, n=105) was the commonest 
indication in starting PPIs. Most of them were 
started PPIs in view of critically ill condition during 
admission where they were intubated requiring 
invasive ventilation. Peptic ulcer disease (28.2%, 
n=46) was the second commonest indication for 
PPIs prescription, followed by erosive esophagitis 
(5.5%, n=9) and GERD (2.0%, n=3) respectively.  
 
 
Figure 2 Patients on PPIs which were indicated according to the FDA guideline 
 
With regard to borderline indications in 
starting PPIs for this study, Figure 3 demonstrated in 
descending frequency were non- steroidal anti-
inflammatory agents (NSAIDs) or antiplatelet 
agents such as aspirin or clopidogrel with the age 
more than 65 years (48.3%,n=116), post critical care 
(19.2%, n=46), anaemia with risk of gastrointestinal 
bleed (12.9%, n=31), double antiplatelet with 
anaemia (8.3%,n=20), uninvestigated dyspepsia 
(5.4%,n=13), double antiplatelet agents (4.2%, 
n=10) and endoscopy (1.7%, n=4).  
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Figure 3 Patients on PPIs which were Borderline Indicated according to the FDA  
guideline 
 
Anaemia with no evidence of 
gastrointestinal bleed was the main non-indication 
in starting PPIs and consisted of 37.6% (129/343). 
Other non-indication in starting PPIs in our study 
were NSAIDs or antiplatelet agents with age less 
than 65 years old (15.2%, n=52), steroid (14.0%, 
n=48), anticoagulant (7.9%, n=27) and biological 
treatment (0.3%, n=1). Surprisingly, up to 25.0% of 
the patients were started on PPIs with no apparent 
indication at all. The administration of PPIs (with no 
apparent indication) had been further confirmed by 
searching through our medical electronic record 
together with the pharmacy records. 
 
 
Figure 4 Patients on PPI which were not indicated according to the FDA guidelines 
 
DISCUSSION 
Our study showed that 23.9% of the consecutive 
medical inpatients were using PPIs. This prevalence 
was lower if compared with Ireland (79.0%),4 
Singapore (46.5%)6 and United States (70.0%).11 In 
Serdang Hospital, all the inpatients must be 
reviewed by a consultant physician at least once 
during the hospitalization. And most of the PPIs in 
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our hospital are of List A, which meant that the valid 
prescription of PPIs could only be made by a 
physician with qualification of specialist level and 
above. This pattern of strict prescription is believed 
to limit the prescription of PPIs in our hospital 
setting. 
However, among those who were initiated 
on PPIs, 46.0% of them were not complied with 
United States FDA guidelines. Anaemia with no 
evidence of gastrointestinal bleed was the main 
reason PPIs were being prescribed inappropriately. 
This finding was similar to some other Asian study 
in where anaemia was the main reason for 
inappropriate prescription of PPIs.6, 7 According to 
guideline, the patients with anaemia are not 
recommended to be routinely initiated with PPI as it 
may result in hyposecretion of gastric acid that may 
affect the iron absorption.12  
It was noted that more than half of patients 
in this study using PPIs were above 60 years old. 
This was reported in many other studies 
demonstrating increasing PPIs prescription among 
elders as well.4, 8, 9,13 However, in general, the age 
itself was not accepted as the independent factor for 
PPI prescription because the elders are always more 
susceptible to illness requiring hospitalization. The 
evidence suggesting potential for inappropriate PPIs 
prescription in elders is high in addition to the 
increased risk for developing clostridium 
difficile infections (CDI) and can lead to 
osteoporosis and fractures if the PPI was used longer 
than eight weeks in the elders.14 As an effort to 
reduce the unnecessary prescription of PPIs in 
elders, the American Geriatrics Society (AGS) had 
added PPI to the 2015 AGS Bears Criteria as 
potentially inappropriate medication use in elders.14 
More male patients were commenced on 
PPIs during hospitalization (P value < 0.05), 
meaning that the gender was significant associated 
with PPIs prescription. This could be explained by 
the relative higher risk of male patients to get peptic 
ulcer disease,15 Helicobacter Pylori infection16 and 
other acid-related disorders. 
Most of our patients didn’t perform any 
OGDS during the hospital stay. In fact, endoscopic 
examination should be performed to justify the need 
for PPIs, especially in those with long term 
prescription. 
PPIs have been used a lot over the years for 
treatment of certain gastrointestinal disorder due to 
the effectiveness of the drug. However, there are 
growing concerns on overuse of PPIs in terms of 
adverse effect as well as healthcare cost. Since 2010, 
FDA has issued safety warnings regarding the long-
term use of PPIs. PPIs are reported to be associated 
with enteric infection such as clostridium difficile, 
osteoporotic bone fractures, increased risk of 
pneumonia, disturbance of antiplatelet function, or 
nutritional deficiencies. Few studies17, 18 have 
demonstrated an increased risk of clostridium 
difficile infections in those with PPIs. This could be 
explained by a higher gastric pH which leads to a 
more virulent strain of bacteria. It was reported a 
41.0% reduction in calcium absorption after two 
weeks of omeprazole therapy.19,20 Long term PPIs is 
potentially associated with higher risk of bone 
fracture.21 Previous studies22,23 have identified an 
increased rate of hospital‐acquired pneumonia and 
recurrent community‐acquired pneumonia in those 
receiving any form of acid suppression therapy, but 
the risk appears to be greater in patients receiving 
PPIs than in those receiving H2 receptor 
antagonists.24 The role of acid suppression in 
increasing risk for pneumonia remains unclear. 
Patients with multiple comorbidities and 
polypharmacy who take long term PPIs are at high 
risk of drug-drug interactions. The alteration of pH 
in the gastrointestinal tract may affect the drug 
absorption, and PPIs inhibit cytochrome (CYP) 
p450 and the p-glycoprotein pathway.25 Gilard et al. 
had found a reduction in the platelet reactivity index 
in 140 patients who took clopidogrel together with 
omeprazole for a week.26  
Furthermore, Angiolillo DJ et al.27 had 
demonstrated the attenuating effects of concomitant 
omeprazole treatment on platelet response to 
clopidogrel, but not between clopidogrel and 
pantoprazole. In 2010, American College of 
Cardiology, American College of Gastroenterology, 
and American Heart Association 
(ACCF/ACG/AHA) released a consensus 
statement28 suggesting the use of PPIs to reduce the 
risk of upper gastrointestinal haemorrhage in 
patients on dual antiplatelet therapy (DAPT). PPI 
was recommended in high risk patients on DAPT, 
especially those of advanced age, previous upper 
gastrointestinal haemorrhage history, H. 
pylori infection, or concurrent utilization of 
NSAIDs, steroids, or anticoagulants.  
Healthcare cost is another point of 
discussion in terms of prescription of PPIs which is 
not according to guideline. Undoubtedly, the 
alarmingly high and inappropriate prescription of 
PPIs will definitely cause increase in healthcare 
cost. Thomas L et al. had published a retrospective 
study showing that 68.8% of the patients in a 
managed care organization at United States, were 
prescribed a PPI inappropriately at hospital 
discharge, with the cost of inappropriate 
prescription of PPIs up to $3,013,069.29 Malaysia is 
a developing country, and the public healthcare is 
fully subsidized by the government. In the 2018 
National Budget, RM27 billion was allocated for the 
healthcare industry. Malaysia's current budget for 
the healthcare is about 4.0% of GDP, but this is still 
lower than the World Health Organisation (WHO) 
recommendation. The rapidly rising cost of drug 
therapy is for sure a great concern to our healthcare 
provider. Therefore, there is a need for us to improve 
our standard in prescribing PPIs according to 
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guidelines. With much wastage of unnecessary PPI 
prescription cost, it could be used for other much 
beneficial indications in terms of improving our 
healthcare.  
As always, education is the key. This had 
been proven in a study performed in West 
Glouchester, United Kingdom showing a reduction 
in PPIs prescription and saving of 1.13 million 
pound after an educational intervention done.30 In 
addition, the primary care improvement program 
which was done in Padua, Italy had shown a 
reduction of PPIs prescription and lowering of cost 
in healthcare as well.31 Health care workers (HCWs) 
should be educated appropriately for management of 
gastrointestinal disorder via continuous medical 
education (CME) and also guidance in prescribing 
PPIs according to guidelines. The pharmacists in the 
hospital can aid in the improvement of PPIs 
prescription. A dedicated pharmacist can be 
assigned during ward rounds as well as to monitor 
the prescription of PPIs on daily basis. Currently, we 
do not have our own clinical guideline of 
prescription of PPIs in Malaysia, except a statement 
published by Malaysian Society of Gastroenterology 
and Hepatology (MSGH) on the use of antiplatelet 
therapy and PPIs in the prevention of 
gastrointestinal bleeding in 2013. A national 
consensus or guideline is warranted to guide in 
prescription of PPIs, not only to clinicians, but 
should be extended to clinical and community 
pharmacists and patients. 
There were few limitations in our study. 
The sample size of the study had been limited due to 
the short duration of the study. The sample data that 
we obtained was from a single hospital which could 
not represent the situation of all hospitals in 
Malaysia.  
 
CONCLUSION 
PPI therapy is not without risk of adverse effects, 
especially if the usage is inappropriate. Our study 
had demonstrated 46.0% of our medical inpatients 
were inappropriately prescribed PPIs. More 
evidence is required to further identify the 
association between long term PPIs and risk of 
adverse effects.   
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